Cerebricon Ltd. : NaytaUutinen

Cerebricon Ltd Becomes Part of the Charles River Laboratories Family

August 5^th, 2009 Kuopio, Finland; Wilmington, MA, USA
Kuopio based Cerebricon has substantially grown during last years and is a fundamental provider of non-clinical Central Nervous System (CNS) services to the pharmaceutical and biotechnology industries. This transaction enables Cerebricon to access the extensive resources and distribution channels of a global service provider.

Cerebricon Ltd., it’s management and employees are delighted to announce that they are now part of the Charles River Discovery and Imaging Services (DIS) business, a global premier provider of non-GLP pharmacology and imaging services. With Cerebricon, the therapeutic areas offered by Charles River will now include CNS, oncology, cardiovascular, metabolism and inflammation.

Cerebricon will continue to function within its laboratories in Kuopio and will continue to serve its clientele and collaborators with the same level of dedication and service that it always has. The main difference now will be the strength and reputation of Charles River as well as becoming an integral part of the wide range of product s and services Charles River offers.

“We are very proud to join become part of Charles River, perhaps the most highly recognized name in the business as far as contract laboratory services go. We (Cerebricon) now become an integral part of a globally recognized company and will now draw on those strengths to become a more substantial service provider in the area of CNS”, stated Juha Yrjanheikki, Cerebricon’s CEO.

For more information:

Managing Director Juha Yrjänheikki, Cerebricon Ltd.
Tel: +358 17 3680 801, email: info@cerebricon.com
www.cerebricon.com

Associate Director of Public Relations, Amy Cianciaruso, Charles River Laboratories, Inc.
www.criver.com

Cerebricon Oy
Charles River Laboratories, Inc.
Based in Wilmington, Massachusetts, USA, Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our approximately 8,500 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.